Silence Therapeutics plc (NASDAQ:SLN) stock is trading higher on Monday after the company reported positive topline outcomes from its Phase 2 SANRECO study assessing divesiran for polycythemia vera.
It is a rare, slow-growing blood cancer where the bone marrow makes too many red blood cells.
The extra production thickens the blood, slows down blood flow, and raises the risk of dangerous blood clots, heart attacks, and strokes.
The mid-stage trial successfully met both its primary and key secondary metrics, demonstrating strong efficacy alongside a favorable safety profile in phlebotomy-dependent trial participants.
Read Also: This $300 Million Biotech May Be Deeply Mispriced: Analyst "The SANRECO Phase 2 trial delivered our best-case outcome, confirming the impressive results observed in Phase 1 with dosing every six weeks and demonstrating equally robust and durable effects with quarterly dosing," said Curtis Rambaran, Chief Medical Officer at Silence.
